Nauticus Robotics has expanded to the United Kingdom and to Norway. Image via nauticusrobotics.com

A Webster-based tech company has officially launched operations in two European countries — and it's only the beginning.

Nauticus Robotics Inc. (NASDAQ: KITT), which went public a few months ago, opened operations in Norway and the United Kingdom, "beginning the company’s international expansion strategy for 2023 and beyond," according to a release from Nauticus. The company develops underwater robots, software, and services to the marine industries.

“The ocean touches nearly every aspect of our lives, yet paradoxically seems to receive less attention and innovation when compared to other sectors,” says Nicolaus Radford, founder and CEO of Nauticus, in the release. “As we expand our operations to these strategic locales and beyond, our core mission remains the same: to become the most impactful ocean robotics company and realize a future where autonomous robotic technologies are commonplace and enable the blue economy for the better."

The two new operating bases are in Stavanger, Norway, and Aberdeen, Scotland. The two outposts will serve the North Sea offshore market. According to the release, Nauticus will work with local partners to service the region’s offshore wind and oil and gas markets. The company will also expand Nauticus Fleet, a "robotic navy of surface and subsea robots," which was established in April of 2022.

These two new regional offices are just the first examples of international growth Nauticus has planned, according to the release. Established to serve as logistics operation centers, the company's expansion plan includes new remote operation centers and service teams around the world in growth markets. The company did not announce any specific expansion plans.

"We are eager to ramp up activities in these international markets as our growing team contributes to our mission," Radford adds.

In October, shortly after its IPO, Nauticus announced that it has been awarded a second multimillion-dollar contract from the U.S. Defense Innovation Unit, part of the U.S. Defense Department, for development of a self-piloted amphibious robot system powered by the company’s ToolKITT command-and-control software.

The company was originally founded in 2014 as Houston Mechatronics Inc. before rebranding in 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.